An Extension Study for Patients Previously Treated With ARQ 501

Completed · Phase 1/Phase 2

Conditions studied: Cancer

In brief

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Key facts

Study ID

NCT00622063

Run by

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

People needed

1

Starts

2006-12-01

Last updated by the study team

2013-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed written informed consent
• Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment

You may not qualify if…

• Have not received previous treatment with ARQ 501 under a treatment protocol
• Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

Where it is running

• Mary Crowley Medical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.